Kovács A, Gyönös I, Magyar J, Bányász T, Nánási P P, Spedding M, Szénási G
Pharmacology Laboratory I, EGIS Pharmaceuticals, Ltd., Budapest, Hungary.
J Cardiovasc Pharmacol. 2001 Jan;37(1):78-88. doi: 10.1097/00005344-200101000-00009.
The I(Kr) blocker EGIS-7229 (S-21407), displays class Ib and class IV effects that may alter its pharmacologic profile compared with those of pure I(Kr) blockers. Therefore, the concentration- and frequency-dependent effects of EGIS-7229, and of the I(Kr) blockers d,l-sotalol and dofetilide, on the effective refractory period (ERP) were measured in isolated right ventricular papillary muscle of the rabbit in vitro. The effects of these drugs on right ventricular fibrillation threshold (RVFT) at increasing intravenous doses were also determined in anesthetized cats. Dofetilide and d,l-sotalol increased ERP in a concentration-dependent manner (dofetilide: 3-100 nM; d,l-sotalol: 3-100 microM) with strong reverse frequency dependence at high concentrations. EGIS-7229 concentration dependently lengthened ERP at 1-30 microM. Its effect on ERP was clearly reverse frequency dependent at 3 microM, but this feature of the drug diminished at 10 microM and was not apparent at 30 microM. The effect of EGIS-7229 (30 microM) on ERP was devoid of reverse frequency dependence as it was more effective (31%) than dofetilide (16 %) at high-pacing rate (3 Hz), whereas it was less effective (50%) than dofetilide (70%) at slow-pacing rate (1 Hz). Reverse frequency-dependent ERP effect of dofetilide (100 nM) was similarly abolished by the addition of lidocaine (30 microM). EGIS-7229 (1-8 mg/kg iv), d,l-sotalol (1-8 mg/kg iv), and dofetilide (10-80 microg/kg iv) caused a dose-dependent increase in RVFT. The minimum effective dose of d,l-sotalol and EGIS-7229 was 1 and 2 mg/kg, respectively, whereas that of dofetilide was 10 microg/kg. EGIS-7229 induced a smaller peak effect in RVFT than sotalol or dofetilide. In conclusion, EGIS-7229 markedly increased refractoriness to electrical stimulation in vitro and in vivo. Compared with pure I(Kr) blockers, the benefits of EGIS-7229 seem to be a greater lengthening of effective refractory period at rapid stimulation rates, suggesting a strong antiarrhythmic action, and a smaller effect at slow stimulation rates, suggesting low potential to induce early afterdepolarizations.
I(Kr)阻滞剂EGIS-7229(S-21407)具有Ib类和IV类效应,与纯I(Kr)阻滞剂相比,其药理特性可能有所改变。因此,在体外兔离体右心室乳头肌中测定了EGIS-7229以及I(Kr)阻滞剂d,l-索他洛尔和多非利特对有效不应期(ERP)的浓度和频率依赖性效应。还在麻醉猫中确定了这些药物静脉注射剂量增加时对右心室颤动阈值(RVFT)的影响。多非利特和d,l-索他洛尔以浓度依赖性方式增加ERP(多非利特:3 - 100 nM;d,l-索他洛尔:3 - 100 μM),在高浓度时具有强烈的反向频率依赖性。EGIS-7229在1 - 30 μM浓度下浓度依赖性地延长ERP。其对ERP的作用在3 μM时明显具有反向频率依赖性,但在10 μM时该药物的这一特性减弱,在30 μM时不明显。EGIS-7229(30 μM)对ERP的作用没有反向频率依赖性,因为在高起搏频率(3 Hz)时它比多非利特(16%)更有效(31%),而在慢起搏频率(1 Hz)时它比多非利特(70%)效果更差(50%)。加入利多卡因(30 μM)同样消除了多非利特(100 nM)的反向频率依赖性ERP效应。EGIS-7229(1 - 8 mg/kg静脉注射)、d,l-索他洛尔(1 - 8 mg/kg静脉注射)和多非利特(10 - 80 μg/kg静脉注射)导致RVFT剂量依赖性增加。d,l-索他洛尔和EGIS-7229的最小有效剂量分别为1和2 mg/kg,而多非利特的最小有效剂量为10 μg/kg。EGIS-7229在RVFT中诱导的峰值效应比索他洛尔或多非利特小。总之,EGIS-7229在体外和体内均显著增加了对电刺激的不应性。与纯I(Kr)阻滞剂相比,EGIS-7229的益处似乎是在快速刺激频率下能更大程度地延长有效不应期,表明其具有强大的抗心律失常作用,而在慢刺激频率下作用较小,表明其诱发早期后去极化的可能性较低。